1. What is Endomedix, Inc.?Endomedix, Inc.
is an early-stage medical device company. The company’s primary focus is the development, patenting and marketing of medical devices using a platform of proprietary technologies to facilitate the improvement of surgical outcomes, simplification of surgical techniques, and reduction of costs for health care providers, while providing superior returns on investment to its shareholders. Endomedix focuses on hydrogel technology within the medical device market for tissue sealant, hemostat and biomedical adhesives. The hydrogel technology is biocompatible and biodegradable with a number of surgical applications, including vascular, spine, and ophthalmologic surgeries, to name a few, as well as non-surgical wound care.
2a. How was Endomedix created? What relationships were involved?
Endomedix, Inc. was founded in 2005 by John Abrahams, MD and Weiliam Chen, PhD. Their collaboration began when Dr. Abrahams, a practicing neurosurgeon and faculty member at Montefiore Medical Center at the time, began looking for a new way to treat cerebral aneurysms. He discovered SUNY assistant professor Dr. Chen’s work with hydrogels and realized that this technology would be perfect for obliterating these deadly vascular abnormalities. The two began to discuss the platform technology and realized that not only could the hydrogel technology be used in endovascular procedures, but it had many other uses as well (e.g., surgical sealant, hemostat, drug-delivery device), and so they created Endomedix, Inc. to help realize this potential.
2b. When did Endomedix first start collaborating with a university?
Endomedix technology was developed by Weiliam Chen, an assistant professor in the Department of Biomedical Engineering at SUNY Stony Brook, and collaboration with the university was in place from the company’s inception.
2c. Does Endomedix have an ongoing relationship with the university or its researchers, and what are the advantages of working with them?
Endomedix, Inc. headquarters is located in the Technology Incubator adjacent to SUNY at Stony Brook. This close proximity to the university and medical center facilitates the sharing of ideas and resources with members of the university. Further studies are being conducted at University of Pennsylvania and the Barrow Neurological Institute.
3. Would you briefly describe Endomedix’s business plan?
Endomedix is focused on bringing to market surgical tissue sealants for use in the fields of cranial and spinal surgery.
4. What is the current status of Endomedix?
Endomedix is currently defining its final specifications for its initial product launch and investigating potential development partners. We anticipate beginning to seek a round of private investment in the very near future.
5. Who is on the Endomedix team?
Richard Russo, President and CEO
John Abrahams, MD, Founder
Weiliam Chen, PhD, Founder
Michael Crupain, MD, Director of Regulatory Affairs
6. How was Endomedix named?
Endomedix was named with the idea that the original focus of the company would be to create embolic agents to be used during ENDOvascular procedures in the field of MEDicine.